Fresenius Kabi Compounding, LLC – FDA 483, Mar 6, 2023
Fresenius Kabi Compounding, LLC in Canton, MA, was cited with two observations during an FDA inspection of its outsourcing facility. The firm failed to follow procedures designed to prevent microbiological contamination of sterile drug products, as operators were observed blocking unidirectional airflow in ISO 5 HLFs. Additionally, the accuracy and suitability of test methods for injectable Vancomycin were not established, as USP <71> sterility tests failed to recover a challenge organism, indicating significant concerns regarding sterility assurance and quality control.
ID · 54f3064d-62c9-4860-be8c-da6a97c83835
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.